A novel pancreatic cancer pill has nearly doubled survival time in a breakthrough trial, surprising experts. The oral drug targets a specific genetic mutation found in a subset of pancreatic tumors, offering new hope for patients with limited options. While the mechanism is still under study, the results are being hailed as a significant advancement in oncology.
Researchers caution that the findings are preliminary and require larger trials, but the initial data has generated considerable excitement in the medical community. The drug's ability to extend survival in such an aggressive cancer marks a critical step forward.